Diabetic neuropathies: clinical manifestations and current treatment options

被引:117
作者
Vinik, A [1 ]
Ullal, J [1 ]
Parson, HK [1 ]
Casellini, CM [1 ]
机构
[1] Strelitz Diabet Res Inst, Neurovasc Unit, Norfolk, VA 23510 USA
来源
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM | 2006年 / 2卷 / 05期
关键词
diabetes mellitus; diabetic autonomic neuropathy; diabetic neuropathy; pain; treatment;
D O I
10.1038/ncpendmet0142
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic neuropathies are a heterogeneous group of disorders that include a wide range of abnormalities. They can be focal or diffuse, proximal or distal, affecting both peripheral and autonomic nervous systems, causing morbidity with significant impact on the quality of life of the person with diabetes, and can result in early death. Distal symmetric polyneuropathy, the most common form of diabetic neuropathy, usually involves small and large nerve Fibers. Small-nerve-fiber neuropathy often presents with pain but without objective signs or electrophysiologic evidence of nerve damage, and is recognized as a component of the impaired glucose tolerance and metabolic syndromes. The greatest risk resulting from small-fiber neuropathy is foot ulceration and subsequent gangrene and amputation. Large-nerve-fiber neuropathies produce numbness, ataxia and uncoordination, impairing activities of daily living and causing falls and fractures. A careful history and detailed physical examination are essential for the diagnosis. Symptomatic therapy has become available and newer and better treatment modalities, based on etiologic factors, are being explored with potential for significant impact on morbidity and mortality. Preventive strategies and patient education still remain key factors in reducing complication rates and mortality.
引用
收藏
页码:269 / 281
页数:13
相关论文
共 78 条
[1]   The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort [J].
Abbott, CA ;
Carrington, AL ;
Ashe, H ;
Bath, S ;
Every, LC ;
Griffiths, J ;
Hann, AW ;
Hussein, A ;
Jackson, N ;
Johnson, KE ;
Ryder, CH ;
Torkington, R ;
Van Ross, ERE ;
Whalley, AM ;
Widdows, P ;
Williamson, S ;
Boulton, AJM .
DIABETIC MEDICINE, 2002, 19 (05) :377-384
[2]  
ALBERS JW, 1995, ANN NEUROL, V38, P478
[5]  
Athyros VG, 1998, ACTA CARDIOL, V53, P201
[6]   Chronic inflammatory demyelinating polyradiculoneuropathy in diabetes mellitus [J].
Ram Ayyar D. ;
Sharma K.R. .
Current Diabetes Reports, 2004, 4 (6) :409-412
[7]   Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus - A randomized controlled trial [J].
Backonja, M ;
Beydoun, A ;
Edwards, KR ;
Schwartz, SL ;
Fonseca, V ;
Hes, M ;
LaMoreaux, L ;
Garofalo, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (21) :1831-1836
[8]   Diabetic neuropathies - A statement by the American Diabetes Association [J].
Boulton, AJM ;
Vinik, AI ;
Arezzo, JC ;
Bril, V ;
Feldman, EL ;
Freeman, R ;
Malik, RA ;
Maser, RE ;
Sosenko, JM ;
Ziegler, D .
DIABETES CARE, 2005, 28 (04) :956-962
[9]   Diabetic somatic neuropathies [J].
Boulton, AJM ;
Malik, RA ;
Arezzo, JC ;
Sosenko, JM .
DIABETES CARE, 2004, 27 (06) :1458-1486
[10]   Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy [J].
Bril, V ;
Buchanan, RA .
DIABETES CARE, 2004, 27 (10) :2369-2375